TLR4 and mastitis: Surprisingly, bta-miR-30a-5p hub miRNA showed the ability to target NFKB1 in addition to TLR4 and STAT3. Therefore, this hub miRNA can have a promising potential to develop therapeutic strategies against mastitis-induced inflammation by targeting the TLR4-NFKB1-STAT3 axis.